

influenza-like symptoms, said the CDC in the November 10, 2000, issue of the *Morbidity and Mortality Weekly Report*. CM is a fungal disease endemic in the southwestern United States and parts of Central and South America. The disease is acquired by inhaling the spores of *Coccidioides immitis*, present in soil. Symptoms are usually mild and influenza-like.

Twenty-seven of 35 church members became ill last winter within 2 weeks after returning from Hermosillo, Mexico, where they had spent a week building a church. Initial testing of acute serum specimens by the CDC showed that 1 member had antibodies to *C immitis*. Subsequently, serum samples and questionnaires were obtained for 30 of the 35 travelers. Of these, 23 reported they had gotten sick in Mexico or after returning home. Serological testing indicated that 8 people, 7 of whom were symptomatic, met the case definition for CM. The most common symptoms were fatigue, fever, and joint and muscle pain; 3 people had a rash, and 4 had a cough. One traveler was hospitalized for a day, and 11 missed work or school (an average of 5.5 days). Eighteen people sought treatment for the illness, and 11 received medications, such as fluconazole or itraconazole.

No activities other than the travel and construction work were associated with the illness. Twenty-two of the church members reported working in very dusty conditions. Approximately 40% of persons infected with *C immitis* experience symptoms, usually mild and influenza-like; however, 8% of patients may develop severe pulmonary disease requiring hospitalization, and 7% develop disseminated extrapulmonary disease. Risk factors for severe pulmonary disease include diabetes, smoking, and older age, whereas risk factors for disseminated disease include black or Asian race, pregnancy, and immunocompromising conditions.

Although avoiding activities that generate dust or using a mask during these activities is advisable, these measures do not provide complete protection from CM. A potential strategy for adequate prevention is vaccine development, because natural infection with *C immitis* provides lifelong immunity. However, until a vaccine becomes available, organizations that conduct trips to areas where CM is endemic should inform their travelers about the risks for CM. Healthcare providers should consider CM in travelers returning from areas where the disease is endemic and who present with an influenza-like illness.

FROM: *icanNEWS*. November 10, 2000.

Community-Acquired MRSA in Queensland, Australia

Community-acquired methicillin-resistant *Staphylococcus aureus* (MRSA) susceptible to gentamicin has been reported in a number of countries in the 1990s. To study the acquisition of gentamicin-sensitive (GS) MRSA in southeast Queensland and the relatedness of GS MRSA to other strains

of MRSA, 35 cases of infection due to GS MRSA from October 1997 through September 1998 were examined retrospectively to determine the mode of acquisition and risk factors for MRSA acquisition.

Thirty-one isolates from the cases were examined using a variety of methods (antibiotyping, phage typing, pulsed-field gel electrophoresis [PFGE] fingerprinting, and coagulase typing by restriction analysis of polymerase chain reaction products) and were compared with strains of local hospital-acquired GS MRSA and of Western Australian (WA) MRSA. Only 6 of 23 cases of community-acquired GS MRSA had risk factors for MRSA acquisition. Twenty of 21 isolates from cases of community-acquired infection were found to be related by PFGE and coagulase typing and had similar phage-typing patterns. Hospital- and nursing home-acquired GS MRSA strains were genetically and phenotypically diverse. Community-acquired GS MRSA strains were not related to nosocomial GR MRSA or WA MRSA, but phage-typing results suggest they are related to GS MRSA previously reported in New Zealand.

FROM: Nimmo GR, Schooneveldt J, O'Kane G, McCall B, Vickery A. Community acquisition of gentamicin-sensitive methicillin-resistant *Staphylococcus aureus* in southeast Queensland, Australia. *J Clin Microbiol* 2000;38:3926-3931.

On-Line Lectures With International Focus

Judene Bartley

The Supercourse: Epidemiology, the Internet, and Global Health web site offers a series of lectures on epidemiology and the Internet in English, Spanish, and Japanese for students of medicine and health. The *British Medical Journal* describes the course as the Global Health Network University. The Supercourse has 1,700 faculty from 110 countries who created a Library of Lectures, with 214 lectures currently available.

The lectures are grouped under the headings New, Revised; Epidemiology and Biostatistics; and Internet and Global Health. Examples of topics include "A Brief Introduction to Epidemiology," "Antibiotics Use and Medical Drug Policy," "Epidemiology of Disasters," "Introduction to Program Evaluation," "Environmental Epidemiology," and "Evidence-Based Medicine: Can We Practice Effectively Without it?" Lectures on specific diseases include, but are not limited to, malaria, cancer, diabetes, and hepatitis. After linking to the index, viewers may simply click on topics and move through the slides and text at their own pace. Hyperlinks within slides permit instant access to sites with related, in-depth information. Interested parties are welcomed to join and either share or review lectures on preferred topics. Go to <http://www.pitt.edu/~super1/>.

Mothers. Spouses. (maybe) Medical Matrix.

What do they have in common? You place your trust in them. When searching the Internet for credible medical information, you need a resource you can trust. *The Lancet* quotes that "Medical Matrix is the most comprehensive compendium of reliable medical information on the Internet."

MEDICAL MATRIX LLC
<http://www.medmatrix.org>

The largest, peer-reviewed directory to the medical Internet.
Free registration.

HOSPITAL EPIDEMIOLOGIST BETH ISRAEL DEACONESS MEDICAL CENTER-BOSTON

Infectious Disease Division seeks full-time Infectious Disease physician to direct Hospital Epidemiology unit and oversee Associate Hospital Epidemiologist and Nurse Epidemiologist in management of daily issues of infection control. Candidate would participate in an active clinical epidemiology research agenda and supervise fellows during research training. Ideal applicant should have advanced training in epidemiology, evidence of research productivity, and recent direct experience in hospital infection control. The position carries an appointment at Harvard Medical School.

The BIDMC is an equal opportunity employer.

Contact: Adolf Karchmer, MD
Beth Israel Deaconess Medical Center
Infectious Disease Division
330 Brookline Avenue
Boston, MA, 02215
Email: akarchme@caregroup.harvard.edu.



The Society for Healthcare Epidemiology of America

2000 SHEA/CDC Training Course in Hospital Epidemiology

Program

The program will be held May 12-15, 2001 at the Jacksonville Hilton and Towers at Jacksonville, FL. Timothy W. Lane, M.D., Julie Gerberding M.D., and Gina Pugliese, R.N., M.S., will co-chair the program. This program, developed by the Society for Healthcare Epidemiology of America (SHEA), and the Centers for Disease Control and Prevention (CDC), is intended for infectious disease fellows and new hospital epidemiologists. It emphasizes hands-on exercises in which participants work in small groups to detect, investigate, and control epidemiological problems encountered in the hospital setting. These work sessions are supplemented with lectures and seminars covering fundamental aspects of hospital epidemiology and surveillance, epidemic investigation, transmission and control of nosocomial infections, disinfection and sterilization, employee health, isolation systems, regulatory compliance, and quality improvement.

Who Should Attend

You should attend if you are a hospital epidemiologist or an infection control practitioner or if you are looking for a course that will provide you with the most current information concerning infection control practices and epidemiological methods in health care. This fundamental program will provide you with opportunities to find solutions to real situations that will occur in the hospital setting. Intensive problem solving sessions are supplemented with lectures and seminars presented by leading authorities.

Jonathan Freeman Scholarships

Seven Jonathan Freeman Scholarships in the amount of \$1,000 each will be awarded to infectious disease fellows for the program to defray the special course fee for fellows of \$400 and expenses incurred in attending the training program.

Interested fellows must submit a letter of no more than one page describing why they would like to have additional training in hospital epidemiology. A letter from the fellow's program director outlining the applicant's qualifications and suitability for the course also is required. The deadline for receipt of scholarship applications

for the course is April 23, 2001. The SHEA Educational Activities Committee will select the scholarship recipients based on review of these letters. Winners will be notified in late April.

Nominations

Please send scholarship applications to:
Timothy W. Lane, M.D.
c/o The Society for Healthcare Epidemiology of America
19 Mantua Road
Mt. Royal, NJ 08061

Fees

Individual Registrants	\$525
Fellows in Infectious Disease	\$400

Credits

The Society for Healthcare Epidemiology of America (SHEA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The Society for Healthcare Epidemiology of America designates this continuing education activity for up to 23 hours in Category 1 of the Physician's Recognition Award of the American Medical Association.

General Course Information

Information regarding the schedule, hotel and travel accommodations, discount airfare, and course fees are available from SHEA (856) 423-7222. Note that application for a scholarship does not constitute enrollment in the program. This must be done separately.

Scholarship Awards provided in part by an educational grant from Pfizer Pharmaceuticals and Wyeth Ayerst Research.